Duvelisib: Hematologic Malignancies
Indolent non-Hodgkin Lymphoma (iNHL)
DYNAMO™: Refractory iNHL
DYNAMO™ is a Phase 2 single-arm, monotherapy study of duvelisib in approximately 120 patients with relapsed indolent non-Hodgkin lymphoma (iNHL). The primary endpoint of the study is response rate. Topline study results were reported in June 2016.
FRESCO: Relapsed/Refractory (R/R) FL
FRESCO is a Phase 2 study designed to evaluate the safety and efficacy of duvelisib plus rituximab versus rituximab in combination with chemotherapy in approximately 230 patients with relapsed/refractory follicular lymphoma. The primary endpoint is progression-free survival.
Chronic Lymphocytic Leukemia (CLL)
DUO™: R/R CLL
DUO™ is an ongoing Phase 3, randomized monotherapy study comparing duvelisib to ofatumumab in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The primary endpoint of the study is progression-free survival. Patient enrollment has been completed.
SYNCHRONY: R/R CLL previously treated with a BTKi therapy
SYNCHRONY is an ongoing Phase 1b, open-label, dose escalation study designed to evaluate the clinical activity and safety of duvelisib in combination with obinutuzumab in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.
This is Phase 1 study is designed to evaluate the safety and clinical activity of IPI-549 in patients with a range of solid tumors, including melanoma and non-small cell lung cancer (NSCLC). The study includes a dose-escalation phase and an expansion phase, and is designed to evaluate IPI-549 as a monotherapy as well as in combination with an anti-PD-1 antibody therapy.